Side effect profile prediction - early addressing of big pharma's worst nightmare
Josef Scheiber, JL Jenkins, Andreas Bender, Steven Whitebread, Jacques Hamon, László Urbán, Khalil Azzaoui, Michael Glick, Jonathan Davies · Chemistry Central Journal · 2008
Adverse effects of drugs that are only identified after a compound enters the clinic seriously limit therapeutic potential and could result in withdrawal from the market.Two well-known examples in recent years were Rofecoxib (Vioxx®) and Cerivastatin (Baycol®, Lipobay®), but there are many other examples.Avoiding such adverse effects is therefore a key goal in drug discovery.